SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Houssiau Frederic)
 

Search: WFRF:(Houssiau Frederic) > (2015-2019) > Off-label use of ri...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Ryden-Aulin, MonicaKarolinska Institutet (author)

Off-label use of rituximab for systemic lupus erythematosus in Europe

  • Article/chapterEnglish2016

Publisher, publication year, extent ...

  • 2016-09-06
  • BMJ,2016

Numbers

  • LIBRIS-ID:oai:lup.lub.lu.se:c24ba2fe-696d-4046-8a41-f2298da25d1c
  • https://lup.lub.lu.se/record/c24ba2fe-696d-4046-8a41-f2298da25d1cURI
  • https://doi.org/10.1136/lupus-2016-000163DOI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:227651920URI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:for swepub-publicationtype
  • Subject category:ref swepub-contenttype

Notes

  • Objectives: Rituximab (RTX) is a biological treatment used off-label in patients with systemic lupus erythematosus (SLE). This survey aimed to investigate the off-label use of RTX in Europe and compare the characteristics of patients receiving RTX with those receiving conventional therapy. Methods: Data on patients with SLE receiving RTX were taken from the International Registry for Biologics in SLE retrospective registry and complemented with data on patients with SLE treated with conventional therapy. For nationwide estimates of RTX use in patients with SLE, investigators were asked to provide data through case report forms (CRFs). Countries for which no data were submitted through CRFs, published literature and/or personal communication were used, and for European countries where no data were available, estimates were made on the assumption of similarities with neighbouring countries. Results: The estimated off-label use of RTX in Europe was 0.5%-1.5% of all patients with SLE. In comparison with patients with SLE on conventional therapy, patients treated with RTX had longer disease duration, higher disease activity and were more often treated with immunosuppressives. The most frequent organ manifestations for which either RTX or conventional therapy was initiated were lupus nephritis followed by musculoskeletal and haematological. The reason for treatment was, besides disease control, corticosteroid-sparing for patients treated with conventional therapy. Conclusions: RTX use for SLE in Europe is restrictive and appears to be used as a last resort in patients for whom other reasonable options have been exhausted.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Boumpas, DimitriosNational and Kapodistrian University of Athens (author)
  • Bultink, IreneAmsterdam Rheumatology and Immunology Center (author)
  • Rubio, Jose Luis CallejasHospital Clínico Universitario San Cecilio (author)
  • Caminal-Montero, LuisAsturias General Hospital (author)
  • Castro, AntoniRovira i Virgili University (URV) (author)
  • Ruiz, Agustín ColodroPasaje Nueva Victoria (author)
  • Doria, AndreaUniversity of Padova (author)
  • Dorner, ThomasCharité - University Medicine Berlin (author)
  • Gonzalez-Echavarri, CristinaUniversity of the Basque Country (author)
  • Gremese, ElisaCatholic University of the Sacred Heart, Rome (author)
  • Houssiau, Frederic A.Saint-Luc University Hospital (author)
  • Huizinga, TomLeiden University Medical Centre (author)
  • Inanc, MuratIstanbul University (author)
  • Isenberg, DavidRoyal Free Hospital (author)
  • Iuliano, AnnamariaAzienda Ospedaliera San Camillo Forlanini (author)
  • Jacobsen, SorenUniversity of Copenhagen (author)
  • Jimenez-Alonso, JuanHospital Clínico Universitario San Cecilio (author)
  • Kovacs, LaszloUniversity of Szeged (author)
  • Mariette, XavierCenter For Immunology Of Viral Infections And Autoimmune Diseases (author)
  • Mosca, MartaUniversity of Pisa (author)
  • Nived, OlaLund University,Lunds universitet,Reumatologi och molekylär skelettbiologi,Sektion III,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Rheumatology,Section III,Department of Clinical Sciences, Lund,Faculty of Medicine,Skåne University Hospital(Swepub:lu)reum-oni (author)
  • Oristrell, JoaquimAutonomous University of Barcelona (author)
  • Ramos-Casals, ManuelInstitutd' Investigacions Biomèdiques August Pi iSunyer (IDIBAPS) (author)
  • Rascon, Javier (author)
  • Ruiz-Irastorza, GuillermoUniversity of the Basque Country (author)
  • Sáez-Comet, LuisMiguel Servet University Hospital (author)
  • Cervello, Gonzalo SalvadorUniversity and Polytechnic Hospital la Fe (author)
  • Sebastiani, Gian DomenicoAzienda Ospedaliera San Camillo Forlanini (author)
  • Squatrito, DaniloUniversity of Florence (author)
  • Szucs, GabriellaUniversity of Debrecen (author)
  • Voskuyl, AlexandreAmsterdam UMC - Vrije Universiteit Amsterdam (author)
  • Van Vollenhoven, RonaldKarolinska Institutet (author)
  • Karolinska InstitutetNational and Kapodistrian University of Athens (creator_code:org_t)

Related titles

  • In:Lupus Science and Medicine: BMJ3:12053-8790

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view